A 62-year-old male with newly diagnosed laryngeal squamous cell carcinoma (T3N1M0) is being staged for treatment planning. After rigid laryngoscopy and biopsy, which imaging modality is most appropriate for comprehensive assessment of nodal involvement and distant metastases?

Explanation

## Staging Investigation for Advanced Laryngeal Carcinoma ### Role of PET-CT in Laryngeal Cancer Staging **Key Point:** PET-CT with ¹⁸F-FDG is the most comprehensive staging investigation for advanced laryngeal carcinoma (T3N1M0). It simultaneously assesses: - Primary tumor metabolic activity and extent - Regional lymph node involvement (detects occult nodal disease) - Distant metastases (lung, bone, liver) - Second primary malignancies (common in head and neck cancer due to field cancerization) ### Advantages of PET-CT Over Conventional Imaging | Feature | PET-CT | CT Chest + CT Neck | CXR + Ultrasound | | --- | --- | --- | --- | | **Nodal detection (N staging)** | High sensitivity for metabolically active nodes | Good but misses small metastatic nodes | Poor | | **Distant metastases** | Detects bone, lung, liver mets in single study | Requires separate studies | Limited sensitivity | | **Second primaries** | Detects occult head/neck and lung primaries | Limited | Very limited | | **Cost-effectiveness** | Single comprehensive study | Multiple modalities needed | Incomplete staging | | **Sensitivity for N1 disease** | 85–95% | 70–80% | <50% | **High-Yield:** In **N1 disease**, PET-CT has superior sensitivity for detecting occult metastatic nodes and ruling out distant spread compared to CT alone. This directly impacts treatment decisions (radiation fields, chemotherapy eligibility). ### Clinical Pearl **Mnemonic: "PET-CT Stages BEST"** - **B**etter sensitivity for nodal disease - **E**xcels at detecting distant metastases - **S**econd primary detection - **T**umor metabolic activity assessment ### When to Use PET-CT - **T3–T4 tumors** (advanced local disease) - **N1–N3 disease** (nodal involvement) - **High-risk histology** (poor differentiation) - **Treatment planning** for radiotherapy/chemotherapy ### Limitations of Alternatives - **CT chest + CT neck:** Anatomically comprehensive but lacks functional/metabolic information; may miss small metastatic nodes and occult distant metastases - **CXR + ultrasound:** Inadequate for staging advanced disease; misses mediastinal nodes, small lung nodules, and distant spread - **MRI neck alone:** Excellent for soft tissue detail but does not assess chest/distant metastases; not a staging tool for M staging